ROR1 and triple-negative breast carcinoma: The combination of CAR T cells targeting the receptor tyrosine kinase-like orphan receptor 1 (ROR1) antigen, which is used for targeted immunotherapy of triple-negative breast cancer, with the TGF-β inhibitor SD-208 led to protection from the immunosuppressive influence of TGF-β and therefore sustained in vitro functionality of CAR T cells [115].